Amgen to build first-of-its-kind biomanufacturing plant in the US10 Apr 2018
Revolutionary, innovative plant offers greater flexibility, speed and efficiency.
Amgen has announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, RI. The new plant, the first of its kind in the US, will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the US and global markets.
A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost of a traditional plant. Next-generation biomanufacturing plants require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions.
"Amgen has three decades of experience in biologics manufacturing, and we are proud of our track record of providing a reliable supply of high-quality medicines for patients around the world," said Esteban Santos, executive vice president of Operations at Amgen. "We are pleased to build the first commercial scale, next-generation biomanufacturing plant in the US, leveraging Amgen's capabilities and incorporating the latest technologies."
A comprehensive evaluation of global locations was conducted to select the location. Following recent US federal tax reform, which provides company incentives to invest in innovation and advanced technologies, Amgen made the decision to locate the new plant in the US. Rhode Island was selected based on the historical success of the Amgen West Greenwich manufacturing facility, its capabilities and talented workforce, and quality of living for staff and potential to grow. The biomanufacturing plant will be built on the current Amgen Rhode Island 75-acre campus and is expected to create approximately 150 additional highly-skilled manufacturing positions and approximately 200 construction and validation jobs.
"I am thrilled that Amgen is planning to expand and bring new, highly skilled jobs to Rhode Island and further enhance the State's life sciences community and manufacturing expertise," said Rhode Island Governor Gina Raimondo. "We welcome Amgen's future healthcare advancements for patients around the world that will come from this new biomanufacturing plant."
Amgen opened its first next-generation biomanufacturing plant in Singapore in 2014. This type of plant offers a highly flexible, modular design which can be replicated in future facilities, which enables Amgen to increase production capabilities reliably with greater speed, productivity and flexibility. Within the plant, the equipment is portable, smaller and disposable, which provides greater flexibility and speed when manufacturing different medicines simultaneously. This eliminates costly and complex retrofitting inherent in standard facilities and allows Amgen to respond to changing demands with increased agility, ultimately impacting the speed at which a medicine is available for patients.
"We are excited that Amgen Rhode Island was chosen as the location to build the new biomanufacturing plant," said Tia Bush, vice president of Operations at Amgen Rhode Island. "It is a testament to our skilled, dedicated workforce and Amgen's continued presence in Rhode Island, which will enable ongoing collaborations with local academic institutions and the broader Rhode Island community."
BIA Separations expands with new upstream processing facility
20 Sep 2018
Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.Read more
Sanofi to refocus two global business units
19 Sep 2018
The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.Read more
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years
18 Sep 2018
China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.Read more
Recipharm connects to European Hub for serialisation compliance
18 Sep 2018
Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.Read more
Bosch to unveil new laboratory device for continuous manufacturing
18 Sep 2018
The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.Read more
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions
17 Sep 2018
Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.Read more
Cambrex expands manufacturing footprint with acquisition
16 Sep 2018
Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.Read more
NMPA approves fruquintinib capsules for metastatic colorectal cancer
13 Sep 2018
Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.Read more
Aptar Pharma to showcase an industry first
12 Sep 2018
PureHale is a new portable drug delivery device designed for upper respiratory care.Read more
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio
11 Sep 2018
The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation